The announcement comes in response to Trump's executive order last month calling for improved rural health and telehealth access.

As COVID-19 continues to spread, an increasing number of rural communities find themselves without their hospital.

When financial incentives like copay coupons and debit cards won't work, pharmaceutical companies sometimes will write a check.

The patenting of a small change in an existing drug is part of a tried-and-true strategy of enveloping products with a series of protective patents.

Promises by the pharmaceutical industry to contain prices are a familiar — and fleeting — phenomenon, say analysts.

The issue of conflicts of interest has become more pressing as drug prices soar and health care companies reach out to the academic and policy community for advice.

In an interview last week, the FDAs Scott Gottlieb said the Orphan Drug Act of 1983 has provided an enormous amount of public health value over the years, but the market has changed.

The nations most influential science advisory group will tell Congress today that the U.S. pharmaceutical market is not sustainable and needs to change.